Zeria Pharmaceutical (TSE:4559) Stock Revenue Climbs While Profit Compression Deepens

Zeria Pharmaceutical came into this quarter with a stock that has drifted lower, down almost 5% over the past three months and about 2% over both the past week and month. Yet the Q1 2027 print lands with a different message. Revenue sits at ¥21,448m and basic earnings per share at ¥19.65, which is a step down from the punchy Q4 numbers. The headline this time is margin and profit pressure rather than growth. That is what the market is trying to price into an already low P/E story.

Love the low P/E angle on Zeria Pharmaceutical but uneasy about the pressure on margins and earnings this quarter? Compare it with a curated set of stocks that pair reasonable valuations with sturdier profitability profiles in our 56 resilient stocks with low risk scores.

Q1 2027 Earnings Summary

• Revenue (Q1 2027 vs. Q1 2026): ¥21,448m vs. ¥19,489m (up about 10%)
• Net Income (Q1 2027 vs. Q1 2026): ¥866m vs. ¥1,090m (down about 21%)
• Basic EPS (Q1 2027 vs. Q1 2026): ¥19.65 vs. ¥24.73 (down about 21%)
• Trailing 12-month Net Income (Q1 2027 TTM vs. Q1 2026 TTM): ¥8,230m vs. ¥6,814m (up about 21%)

Prefer clear visual charts over pages of earnings tables and ratios for Zeria Pharmaceutical? Get a full picture of how the business is priced by the market with an at a glance view of its valuation in the company report for Zeria Pharmaceutical.

Revenue Growth Supports Zeria Pharmaceutical’s Defensive Angle

For investors leaning toward the defensive healthcare story, Zeria Pharmaceutical still offers some support. Revenue in Q1 2027 is ¥21,448m compared with ¥19,489m a year earlier, which backs the idea of ongoing demand across prescription GI and OTC lines. Trailing 12 month net income of ¥8,230m versus ¥6,814m a year earlier points to healthier earnings over the broader period. That fits a view of a mature business that can still grow its profit pool over time, even if quarterly results move around.

Margin Pressure Tests The “Steady Compounder” Narrative

The bearish angle focuses on earnings quality, and Q1 2027 gives that view some weight. Net income fell from ¥1,090m to ¥866m and basic EPS went from ¥24.73 to ¥19.65. That points to margin pressure even with higher sales. Recent share price weakness over 7, 30 and 90 days also signals that investors are treating Zeria Pharmaceutical more cautiously. The broader earnings trajectory still looks solid on a trailing 12 month view, but the near term pattern is more about profit compression than smooth, steady progress.

Track how Zeria Pharmaceutical’s revenue growth and trailing 12 month earnings stack up against the recent margin squeeze, then consider whether analysts view this as a temporary setback or a more fundamental reset in the story. Compare that internal progress with external expectations in the consensus price target analysis for Zeria Pharmaceutical

Stay Ahead With Simply Wall St

If the mix of revenue growth and margin pressure at Zeria Pharmaceutical has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a more attractive entry point. Once you own shares, keep your focus on what matters most with the Portfolio Command Center that highlights key earnings, valuation and risk updates without flooding you with noise. For a wider view on how other investors are thinking about Zeria Pharmaceutical and similar stocks, join the conversation through the Community. By spotting potential catalysts and risks early, you give yourself a better chance to act with confidence and stay ahead of the market.

Seeking Alternatives Beyond Zeria Pharmaceutical

Fresh stock ideas can move quickly, and momentum often builds once a wider group of investors takes notice. Explore what may still be under the radar for now and consider your options promptly.

• Identify companies with sturdier balance sheets before momentum accelerates by running your filters through the curated list of solid balance sheet and fundamentals stocks (40 results) that surfaces businesses with stronger financial footing.
• Explore income opportunities that could be more resilient when prices are declining by reviewing a hand picked set of high yielding stocks in the 43 dividend fortresses curated list.
• Look for potential future growth stories that may still be under the radar by scanning the carefully filtered 63 high quality undiscovered gems that highlights quality companies investors may be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com